INDV (Indivior PLC) צמיחה צפויה ברווח נקי למניה השנה

Indivior PLC dominates opioid addiction therapy due to its unique clinical expertise and high barriers to entry. The annual percentage growth in net income per share clearly demonstrates the profitability trend, while the 23.10 metric confirms the current level. Production has been outsourced to external partners under strict GMP control. Patent protection for Sublocade and government support provide Indivior PLC with significant pricing power.

This indicator measures the year-over-year dynamics of earnings per share, identifying whether growth is driven by real margin expansion or the artificial impact of share buybacks. By analyzing the annual trajectory of earnings per share, an investor can assess the sustainability of Indivior PLC (INDV), where stable demand for addiction treatments should offset legal risks and generic pressure.